Project Name: Multiple Sclerosis (MS) Capacity Redesign Collaborative Working Project (CWP)

Project Summary:

The CWP aims to foster collaboration between Novartis Pharmaceuticals UK Limited and North West Anglia NHS Foundation Trust to enhance the multiple sclerosis service delivery for patients with relapsing remitting multiple sclerosis (RRMS). Through this partnership, the organisations seek to leverage their combined expertise to improve patient outcomes and streamline healthcare processes. The ultimate goal is to develop innovative solutions that address the challenges faced by patients diagnosed with relapsing remitting multiple sclerosis, and provide more efficient, effective care.

Success of the project will be measured by the following KPIs:

  1. The transfer of patient care from Cambridge University Hospital back to the CW Partner’s MS Service for all of the CW Partner’s MS patients.
  2. Patient reviews will increase as a consequence of the increase in headcount, which may lead to increased assessments regarding the suitability of HET.
  3. The submission of a business case for future funding of the project roles post project.

By continuously monitoring these metrics, the project seeks to ensure tangible improvements in healthcare provision and patient well-being.

Milestones:

Milestone 1: Project kick-off meeting.

Milestone 2: Baseline data. Clinic protocols. 

Milestone 3: Hire of the project role (nurse). 

Milestones 4 to 11: clinical activity with data submission and project review every 3 months and business case submission at milestone 8.

Milestone 12: Project outcomes.

Expected Benefits: 

Patient

  • Improved patient outcomes due to faster time from referral to treatment time.
  • Improved access to NICE recommended therapies.
  • Enhanced patient experience of the NHS MS service by reducing unnecessary waiting times.

CW Partner (Ie: NHS)

  • Improved quality of care.
  • Reduction in patient waiting lists.
  • Improved MDT efficiency and outcomes.
  • Improved experience of staff by spreading workload.

Novartis

  • Novartis is likely to see positive outcomes as a result of the collaborative working project with North West Anglia NHS Foundation Trust. By enhancing the multiple sclerosis service delivery, the project aims to improve patient outcomes for those patients with relapsing remitting multiple sclerosis (RRMS). As more patients are reviewed, there is potential for greater utilisation of Novartis's medicines, in line with national and local guidelines, where appropriate, leading to improved patient care.
  • To assist in the redesign and better use of the RRMS management patient pathway, improved understanding of the pressure points and priorities associated with the MS service and backlog of patients pending reviews. This will enable Novartis to build better projects in this therapy area in other regions of the UK with an aim to help more RRMS patients receive a timely review.

Start Date & Duration: May 2025 for 33 months or project completion, whichever should first occur.

FA-11414266 | April 2025